Table 2.
New strategies in 2WT mCRC patients after anti-EGFR progression.
| Author | Design(n) | Treatment arms | LLB at Entry * | Biomarker Driven **/Targeted Therapy BiBiomarker Driven **/Targeted Therapyomarker Selection | BOR% | PFS (m) | mOS (m) | ESMO-MCBS: ESMO-Magnitude Clinical Benefit Scale |
|---|---|---|---|---|---|---|---|---|
| Montagut et al. [94] | II-R (254) | Sym004-12 mg/kg vs. Sym004-9 mg/kg vs. Investigator choice | No | No | 14.1 9.6 2.9 |
- - - |
11.9 8.9 8.4 |
1 |
| Cremolini et al. [96] | II (28) | Irinotecan-Cetuximab | No | No | 14 | 4.1 ** | - | NA |
| Rimassa et al. [97] | II (41) | Tivantinib-Cetuximab | No | No | 9.8 | 2.6 | - | NA |
| Delord et al. [98] | I-II (13) | Capmatinib-Cetuximab | No | No | 0 | - | - | NA |
| Sartore-Bianchi et al. [99] | II (27) | Trastuzumab-Lapatinib | No | Yes/HER2 (+++) | 26 | 5.1 | - | NA |
| Nakamura et al. [100] | II (18) | Trastuzumab-Pertuzumab | Yes | Yes/HER2 (amplification) | 35 | 4 | - | NA |
| Gupta et al. [101] | II (28) | Trastuzumab-Pertuzumab | No | Yes/HER2 (+++) | 25 | 4.2 | - | NA |
| Sartore-Bianchi et al. [102] | II (31) | TDM1-Pertuzumab | No | Yes/HER2 (+++) | 9.7 | 4.1 | - | NA |
| Siena et al. [103] | II (53) | Trastuzumab-Deruxtecan | No | Yes/HER2 (+++) | 43.4 | 6.9 | - | NA |
| CHRONOS * | II (129) | Panitumumab | Yes | No | - | - | - | - |
| BEYOND * | II-R (85) | FOLFIRI-Panitumumab vs FOLFIRI | Yes | No | - | - | - | - |
| VELO * | II-R (112) | TAS-102-Panitumumab vs TAS-102 | No | No | - | - | - | - |
| PULSE * | II-R (106) | Panitumumab vs Regorafenib or TAS-102 | Yes | No | - | - | - | - |
| FIRE-4 * | III (230) | Irinotecan-Cetuximab vs Regorafenib or Investigator choice | No | No | - | - | - | - |
| PERSPECTIVE * | II (48) | Tepotinib-Cetuximab | Yes | Yes/MET (amplification) | - | - | - | - |
2WT, double wild-type for RAS and BRAF mutations; N, number; LB, liquid biopsy; BOR, best overall response; mPFS, median progression-free survival in months; mOS, median overall survival in months; ESMO-MCBS, ESMO-Magnitude Clinical Benefit Scale; NA, not applicable. * Prospective studies without available results. ** Patients without mutations in liquid biopsy. (+++) Amplification 3 crosses.